{
    "name": "galsulfase",
    "comment": "Rx",
    "other_names": [
        "Naglazyme"
    ],
    "classes": [
        "Enzymes",
        "Metabolic"
    ],
    "source": "https://reference.medscape.com/drug/naglazyme-galsulfase-342893",
    "pregnancy": {
        "common": [
            "Available data from case reports and postmarketing experience with use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Clinical considerations",
                "description": [
                    "Pregnancy can exacerbate preexisting clinical manifestations of MPS and lead to adverse pregnancy outcomes for both mother and fetus"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of galsulfase in human milk, the effects on the breastfed infant, or the effects on milk production",
            "Consider developmental and health benefits of breastfeeding along with the mother’s clinical need and any potential adverse effects on the breastfed infant or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None listed in the manufacturer's label"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Anaphylaxis and severe allergic reactions have been observed during and up to 24 hr after infusion; some reactions were life-threatening and included anaphylaxis, shock, respiratory distress, dyspnea, bronchospasm, laryngeal edema, and hypotension",
                "Type III immune complex-mediated reactions, including membranous glomerulonephritis, observed with enzyme replacement therapies",
                "Caution in patients susceptible to fluid volume overload (eg, weight ≤20 kg, acute underlying respiratory illness, compromised cardiac and/or respiratory function) because CHF may result",
                "Because of the potential for infusion reactions, patients should receive antihistamines with or without antipyretics prior to infusion; infusion reactions may still occur despite of premedication; decrease rate of infusion if it occurs or discontinue immediately if reaction is severe; use caution with readministration",
                "Sleep apnea is common in patients with MPS VI and antihistamine pretreatment may increase the risk of apneic episodes",
                "Spinal or cervical cord compression (SCC) with resultant myelopathy is a known and serious complication of MPS VI; SCC is expected to occur in the natural history of the disease, including in patients on galsulfase; there are postmarketing reports of onset or worsening of SCC requiring decompression surgery",
                "Consider postponing treatment in patients with acute febrile or respiratory illness",
                "Excess agitation of solutioni prior to or after dilution may denature and inactivate galsulfase",
                "A registry has been created to track adverse effects, and monitor therapeutic responses during long-term treatment; may contact 1-800-983-4587 or at www.naglazyme.com/en/clinical-resources/surveillance-program.aspx"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Abdominal pain",
            "percent": "53"
        },
        {
            "name": "Ear pain",
            "percent": "42"
        },
        {
            "name": "Conjunctivitis",
            "percent": "21"
        },
        {
            "name": "Dyspnea",
            "percent": "21"
        },
        {
            "name": "Rigors",
            "percent": "21"
        },
        {
            "name": "Chest pain",
            "percent": "16"
        },
        {
            "name": "Pharyngitis",
            "percent": "16"
        },
        {
            "name": "Areflexia",
            "percent": "11"
        },
        {
            "name": "Face edema",
            "percent": "11"
        },
        {
            "name": "Gastroenteritis",
            "percent": "11"
        },
        {
            "name": "HTN",
            "percent": "11"
        },
        {
            "name": "Increased corneal opacification",
            "percent": "11"
        },
        {
            "name": "Malaise",
            "percent": "11"
        },
        {
            "name": "Nasal congestion",
            "percent": "11"
        },
        {
            "name": "Umbilical hernia",
            "percent": "11"
        },
        {
            "name": "Bronchospasm",
            "percent": null
        },
        {
            "name": "Erythema",
            "percent": null
        },
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Tachypnea",
            "percent": null
        },
        {
            "name": "Shock",
            "percent": null
        },
        {
            "name": "Cyanosis",
            "percent": null
        },
        {
            "name": "Hypoxia",
            "percent": null
        }
    ]
}